Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Macrogenics Inc.
Headquarters: Rockville, MD, United States of America
Website: http://www.macrogenics.com
Year Founded: 2000
Status: Public
Industry Sector: HealthTechnology
CEO: Scott E. Koenig, MD, PhD
Number Of Employees: 341
Enterprise Value: $39,312,851
PE Ratio: -1.07
Exchange/Ticker 1: NASDAQ:MGNX
Exchange/Ticker 2: N/A
Latest Market Cap: $76,970,200
BioCentury | Nov 1, 2024
Management Tracks
Masashi Miyamoto to become chairman and CEO of Kyowa Kirin
Plus: Scott Koenig to step down as CEO of MacroGenics, and updates from Axonis and Myrobalan
BioCentury | Sep 6, 2024
Distillery Therapeutics
CAR T cells targeting FGFR4 and B7-H3 for pediatric rhabdomyosarcoma
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | May 14, 2024
Data Byte
The diverse modalities targeting B7-H3
ADCs against the target have raised safety concerns, but companies are hitting B7-H3 with other modalities
BioCentury | May 14, 2024
Product Development
Clinical Report: MacroGenics faces ADC safety concerns
Plus data from CytomX, Merck, Regeneron and more
BioCentury | Mar 13, 2023
Deals
Sanofi takeout of Provention puts disease interception to the commercial test
Sanofi acquiring Provention for $2.9B to take over Type I diabetes launch, advance disease interception pipeline
BioCentury | Nov 19, 2022
Market Access
Nov. 18 Quick Takes: Provention prices first-ever therapy to delay diabetes progression
Plus: Apellis shares bounce as FDA accepts amended NDA, and updates from Iovance, RAPT, G1, Lysogene and RongCan
BioCentury | Nov 18, 2022
Regulation
Nov. 17 Quick Takes: FDA approves Provention’s mAb to slow onset of diabetes
Plus: Rezo’s launch, deals by Regeneron-CytomX and Marinus-Tenacia, the end of a GSK-Immatics deal, and Tenaya’s funding
BioCentury | Nov 2, 2022
Data Byte
At least seven PDUFA dates on deck in November
Agents up for their first approval include Apellis’ geographic atrophy therapy and Provention’s diabetes interception program
Items per page:
1 - 10 of 221